Dr Reddy's Laboratories Enters Strategic Collaboration with Amgen to Market Innovative Medicines in India

Strategic Insights -

Dr Reddy's Laboratories Ltd, a leading pharmaceutical company, has collaborated with US-based biotechnology giant Amgen Inc to market and distribute three of Amgen's innovative medicines in India. These medicines, Kyprolis, Blincyto, and Repatha, cater to the areas of oncology and cardiology, addressing significant unmet needs of patients in India. The collaboration combines Amgen's innovative therapies with Dr Reddy's understanding of patient and physician needs in India.

Key Takeaways:

  • Dr Reddy's Laboratories has entered into a strategic collaboration with Amgen Inc to market and distribute three of Amgen's medicines in India, namely Kyprolis, Blincyto, and Repatha.
  • The collaboration focuses on addressing significant unmet needs of patients in oncology and cardiovascular areas in India.
  • Kyprolis or carfilzomib has been approved by the US FDA for the treatment of patients with relapsed multiple myeloma and is also indicated under FDA accelerated approval as a single agent for the treatment of patients with multiple myeloma.
  • Blincyto or blinatumomab is a monoclonal antibody used for the treatment of Acute Lymphoblastic Leukemia (ALL), a type of Leukemia.
  • Repatha or evolocumab is used for the treatment of patients with uncontrolled cholesterol despite taking maximum doses of statins or for those who cannot take statins and require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.
  • The collaboration leverages the capabilities of both companies, combining Amgen's innovative therapies with Dr Reddy's understanding of patient and physician needs in India.
  • Alok Sonig, executive vice-president and head of India business and global business development of Dr Reddy's, said, "We are excited about our strategic collaboration with an innovation powerhouse like Amgen and look forward to making their innovative medicines accessible to Indian patients."
  • Penny Wan, vice-president and general manager, Japan and Asia Pacific region, Amgen, said, "We are pleased to be joining forces with Dr Reddy's Laboratories in order to make Amgen's innovative medicines available to patients in India."

Statistics:

  • The collaboration will see the launch of three innovative medicines in India, addressing significant unmet needs in oncology and cardiovascular areas.
  • Kyprolis has been approved by the US FDA for the treatment of patients with relapsed multiple myeloma and is also indicated under FDA accelerated approval as a single agent for the treatment of patients with multiple myeloma.
  • Blincyto was approved by the FDA in 2014 for the treatment of Acute Lymphoblastic Leukemia (ALL).
  • Repatha or evolocumab was approved by the European Commission in July for the treatment of patients with uncontrolled cholesterol despite taking maximum doses of statins or for those who cannot take statins and require additional intensive low-density lipoprotein cholesterol (LDL-C) reduction.
  • Shares of Dr. Reddy's gained as much as 3% on the BSE, while the benchmark Sensex declined 0.04% on the day of the announcement.

Sources:

  • "Dr Reddy's Laboratories signs deal with Amgen to market three drugs in India" by Mint, published online, no date mentioned